{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:24:58Z","timestamp":1793121898708,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T00:00:00Z","timestamp":1587772800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T00:00:00Z","timestamp":1587772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Niemann-Pick disease Type C (NP-C) is a rare, progressive neurodegenerative disorder characterized by progressive neurodegeneration and premature death. We report data at closure of the NPC Registry that describes the natural history, disease course and treatment experience of NP-C patients in a real-world setting.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>The NPC Registry was a prospective observational cohort study that ran between September 2009 and October 2017. Patients with a confirmed diagnosis of NP-C were enrolled regardless of treatment status. All patients underwent clinical assessments and medical care as determined by their physicians; data were collected through a secure internet-based portal.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>At closure on October 19, 2017, 472 patients from 22 countries were enrolled in the NPC Registry. Mean (standard deviation) age at enrollment was 21.2 (15.0) years, and 51.9% of patients were male. First neurological symptom onset occurred during the early-infantile (&lt;\u20092\u2009years), late-infantile (2 to &lt;\u20096\u2009years), juvenile (6 to &lt;\u200915\u2009years), or adolescent\/adult (\u2265\u00a015\u2009years) periods in 13.5, 25.6, 31.8, and 29.1% of cases, respectively. The most frequent neurological manifestations prior to enrollment included ataxia (67.9%), vertical supranuclear gaze palsy (67.4%), dysarthria (64.7%), cognitive impairment (62.7%), dysphagia (49.1%), and dystonia (40.2%). During infancy, splenomegaly and hepatomegaly were frequent (<jats:italic>n<\/jats:italic>\u2009=\u2009199\/398 [50%] and <jats:italic>n<\/jats:italic>\u2009=\u2009147\/397 [37.0%], respectively) and persisted in most affected patients. Of the 472 enrolled patients, 241 were continuously treated with miglustat during the NPC Registry observation period, of whom 172 of these 241 patients were treated continuously for \u226512\u2009months. A composite disability score that assesses impairment of ambulation, manipulation, language, and swallowing was highest in the early-infantile population and lowest in the adolescent\/adult population. Among the continuous miglustat therapy population, 70.5% of patients had improved or had stable disease (at least 3 of the 4 domains having a decreased or unchanged score between enrollment and last follow-up). The NPC Registry did not identify any new safety signals associated with miglustat therapy.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The profiles of clinical manifestations in the final NPC Registry dataset agreed with previous clinical descriptions. Miglustat therapy was associated with a stabilization of neurological manifestations in most patients. The safety and tolerability of miglustat therapy was consistent with previous reports.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13023-020-01363-2","type":"journal-article","created":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T16:02:22Z","timestamp":1587830542000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["Treatment outcomes following continuous miglustat therapy in patients with Niemann-Pick disease Type C: a final report of the NPC Registry"],"prefix":"10.1186","volume":"15","author":[{"given":"Marc C.","family":"Patterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Mengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie T.","family":"Vanier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Moneuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,25]]},"reference":[{"key":"1363_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1750-1172-8-12","volume":"8","author":"MC Patterson","year":"2013","unstructured":"Patterson MC, Mengel E, Wijburg FA, Muller A, Schwierin B, Drevon H, et al. Disease and patient characteristics in NP-C patients: findings from an international disease registry. Orphanet J Rare Dis. 2013;8:12.","journal-title":"Orphanet J Rare Dis"},{"key":"1363_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1750-1172-5-16","volume":"5","author":"MT Vanier","year":"2010","unstructured":"Vanier MT. Niemann-Pick disease type C. Orphanet J Rare Dis. 2010;5:16.","journal-title":"Orphanet J Rare Dis"},{"key":"1363_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13023-018-0785-7","volume":"13","author":"T Geberhiwot","year":"2018","unstructured":"Geberhiwot T, Moro A, Dardis A, Ramaswami U, Sirrs S, Marfa MP, et al. Consensus clinical management guidelines for Niemann-Pick disease type C. Orphanet J Rare Dis. 2018;13:50.","journal-title":"Orphanet J Rare Dis"},{"key":"1363_CR4","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ymgme.2012.03.012","volume":"106","author":"MC Patterson","year":"2012","unstructured":"Patterson MC, Hendriksz CJ, Walterfang M, Sedel F, Vanier MT, Wijburg F, et al. Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. Mol Genet Metab. 2012;106:330\u201344.","journal-title":"Mol Genet Metab"},{"key":"1363_CR5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1034\/j.1399-0004.2003.00147.x","volume":"64","author":"MT Vanier","year":"2003","unstructured":"Vanier MT, Millat G. Niemann-Pick disease type C. Clin Genet. 2003;64:269\u201381.","journal-title":"Clin Genet"},{"key":"1363_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/gim.2015.25","volume":"18","author":"CA Wassif","year":"2016","unstructured":"Wassif CA, Cross JL, Iben J, Sanchez-Pulido L, Cougnoux A, Platt FM, et al. High incidence of unrecognized visceral\/neurological late-onset Niemann-Pick disease, type C1, predicted by analysis of massively parallel sequencing data sets. Genet Med. 2016;18:41\u20138.","journal-title":"Genet Med"},{"key":"1363_CR7","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ymgme.2009.06.008","volume":"98","author":"JE Wraith","year":"2009","unstructured":"Wraith JE, Baumgartner MR, Bembi B, Covanis A, Levade T, Mengel E, et al. Recommendations on the diagnosis and management of Niemann-Pick disease type C. Mol Genet Metab. 2009;98:152\u201365.","journal-title":"Mol Genet Metab"},{"key":"1363_CR8","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/ajmg.a.31735","volume":"143A","author":"WS Garver","year":"2007","unstructured":"Garver WS, Francis GA, Jelinek D, Shepherd G, Flynn J, Castro G, et al. The National Niemann-Pick C1 disease database: report of clinical features and health problems. Am J Med Genet A. 2007;143A:1204\u201311.","journal-title":"Am J Med Genet A"},{"key":"1363_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12883-015-0511-1","volume":"15","author":"J Imrie","year":"2015","unstructured":"Imrie J, Heptinstall L, Knight S, Strong K. Observational cohort study of the natural history of Niemann-Pick disease type C in the UK: a 5-year update from the UK clinical database. BMC Neurol. 2015;15:257.","journal-title":"BMC Neurol"},{"key":"1363_CR10","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S0022-3476(05)81695-6","volume":"123","author":"DA Kelly","year":"1993","unstructured":"Kelly DA, Portmann B, Mowat AP, Sherlock S, Lake BD. Niemann-Pick disease type C: diagnosis and outcome in children, with particular reference to liver disease. J Pediatr. 1993;123:242\u20137.","journal-title":"J Pediatr"},{"key":"1363_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2006.05.054","volume":"249","author":"C Iturriaga","year":"2006","unstructured":"Iturriaga C, Pineda M, Fernandez-Valero EM, Vanier MT, Coll MJ. Niemann-Pick C disease in Spain: clinical spectrum and development of a disability scale. J Neurol Sci. 2006;249:1\u20136.","journal-title":"J Neurol Sci"},{"key":"1363_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13023-015-0284-z","volume":"10","author":"MC Patterson","year":"2015","unstructured":"Patterson MC, Mengel E, Vanier MT, Schwierin B, Muller A, Cornelisse P, et al. Stable or improved neurological manifestations during miglustat therapy in patients from the international disease registry for Niemann-Pick disease type C: an observational cohort study. Orphanet J Rare Dis. 2015;10:65.","journal-title":"Orphanet J Rare Dis"},{"key":"1363_CR13","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13023-014-0140-6","volume":"9","author":"H Jahnova","year":"2014","unstructured":"Jahnova H, Dvorakova L, Vlaskova H, Hulkova H, Poupetova H, Hrebicek M, et al. Observational, retrospective study of a large cohort of patients with Niemann-Pick disease type C in the Czech Republic: a surprisingly stable diagnostic rate spanning almost 40 years. Orphanet J Rare Dis. 2014;9:140.","journal-title":"Orphanet J Rare Dis"},{"key":"1363_CR14","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ymgme.2009.06.009","volume":"98","author":"JE Wraith","year":"2009","unstructured":"Wraith JE, Guffon N, Rohrbach M, Hwu WL, Korenke GC, Bembi B, et al. Natural history of Niemann-Pick disease type C in a multicentre observational retrospective cohort study. Mol Genet Metab. 2009;98:250\u20134.","journal-title":"Mol Genet Metab"},{"key":"1363_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s10545-013-9626-y","volume":"37","author":"JE Wraith","year":"2014","unstructured":"Wraith JE, Sedel F, Pineda M, Wijburg FA, Hendriksz CJ, Fahey M, et al. Niemann-Pick type C Suspicion Index tool: analyses by age and association of manifestations. J Inherit Metab Dis. 2014;37:93\u2013101.","journal-title":"J Inherit Metab Dis"},{"key":"1363_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13023-019-0996-6","volume":"14","author":"M Pineda","year":"2019","unstructured":"Pineda M, Jurickova K, Karimzadeh P, Kolnikova M, Malinova V, Insua JL, et al. Disease characteristics, prognosis and miglustat treatment effects on disease progression in patients with Niemann-Pick disease Type C: an international, multicenter, retrospective chart review. Orphanet J Rare Dis. 2019;14:32.","journal-title":"Orphanet J Rare Dis"},{"key":"1363_CR17","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1212\/CPJ.0000000000000399","volume":"7","author":"MC Patterson","year":"2017","unstructured":"Patterson MC, Clayton P, Gissen P, Anheim M, Bauer P, Bonnot O, et al. Recommendations for the detection and diagnosis of Niemann-Pick disease type C: an update. Neurol Clin Pract. 2017;7:499\u2013511.","journal-title":"Neurol Clin Pract"},{"key":"1363_CR18","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1177\/0883073809344222","volume":"25","author":"MC Patterson","year":"2010","unstructured":"Patterson MC, Vecchio D, Jacklin E, Abel L, Chadha-Boreham H, Luzy C, et al. Long-term miglustat therapy in children with Niemann-Pick disease type C. J Child Neurol. 2010;25:300\u20135.","journal-title":"J Child Neurol"},{"key":"1363_CR19","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1474-4422(07)70194-1","volume":"6","author":"MC Patterson","year":"2007","unstructured":"Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 2007;6:765\u201372.","journal-title":"Lancet Neurol"},{"key":"1363_CR20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ymgme.2009.12.006","volume":"99","author":"JE Wraith","year":"2010","unstructured":"Wraith JE, Vecchio D, Jacklin E, Abel L, Chadha-Boreham H, Luzy C, et al. Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial. Mol Genet Metab. 2010;99:351\u20137.","journal-title":"Mol Genet Metab"},{"key":"1363_CR21","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1080\/15622975.2017.1379610","volume":"20","author":"O Bonnot","year":"2019","unstructured":"Bonnot O, Gama CS, Mengel E, Pineda M, Vanier MT, Watson L, et al. Psychiatric and neurological symptoms in patients with Niemann-Pick disease type C (NP-C): findings from the international NPC Registry. World J Biol Psychiatry. 2019;20:310\u20139.","journal-title":"World J Biol Psychiatry"},{"key":"1363_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13023-018-0913-4","volume":"13","author":"Y Nadjar","year":"2018","unstructured":"Nadjar Y, H\u00fctter-Moncada AL, Latour P, Ayrignac X, Kaphan E, Tranchant C, et al. Adult Niemann-Pick disease type C in France: clinical phenotypes and long-term miglustat treatment effect. Orphanet J Rare Dis. 2018;13:175.","journal-title":"Orphanet J Rare Dis"},{"key":"1363_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13023-018-0844-0","volume":"13","author":"M Pineda","year":"2018","unstructured":"Pineda M, Walterfang M, Patterson MC. Miglustat in Niemann-Pick disease type C patients: a review. Orphanet J Rare Dis. 2018;13:140.","journal-title":"Orphanet J Rare Dis"},{"key":"1363_CR24","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s00415-016-8051-1","volume":"263","author":"F Sedel","year":"2016","unstructured":"Sedel F, Chabrol B, Audoin B, Kaphan E, Tranchant C, Burzykowski T, et al. Normalisation of brain spectroscopy findings in Niemann-Pick disease type C patients treated with miglustat. J Neurol. 2016;263:927\u201336.","journal-title":"J Neurol"},{"issue":"Suppl 3","key":"1363_CR25","doi-asserted-by":"publisher","first-page":"S379","DOI":"10.1007\/s10545-010-9193-4","volume":"33","author":"H Champion","year":"2010","unstructured":"Champion H, Ramaswami U, Imrie J, Lachmann RH, Gallagher J, Cox TM, et al. Dietary modifications in patients receiving miglustat. J Inherit Metab Dis. 2010;33(Suppl 3):S379\u201383.","journal-title":"J Inherit Metab Dis"},{"key":"1363_CR26","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s10545-011-9368-7","volume":"34","author":"N Belmatoug","year":"2011","unstructured":"Belmatoug N, Burlina A, Giraldo P, Hendriksz CJ, Kuter DJ, Mengel E, et al. Gastrointestinal disturbances and their management in miglustat-treated patients. J Inherit Metab Dis. 2011;34:991\u20131001.","journal-title":"J Inherit Metab Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01363-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-020-01363-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01363-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,24]],"date-time":"2021-04-24T23:46:30Z","timestamp":1619307990000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01363-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,25]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1363"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01363-2","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,25]]},"assertion":[{"value":"29 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Before enrollment into the Registry, the patient and\/or legal guardian must have signed a Patient Informed Consent Form, which authorized data collection.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MCP has been a member of Actelion Pharmaceuticals Ltd. Advisory Board, and has received honoraria for talks from Actelion Pharmaceuticals Ltd.EM has been a member of Actelion Pharmaceuticals Ltd. Advisory Board, and has received honoraria for talks and\/or research grants from Actelion Pharmaceuticals Ltd.MTV has been a member of Actelion Pharmaceuticals Ltd. Advisory Board, and has received travel reimbursement and honoraria for talks from Actelion Pharmaceuticals Ltd.PM and DR are employees of Actelion Pharmaceuticals Ltd.MP has received honoraria for talks and travel reimbursement from Actelion Pharmaceuticals Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}